Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome

Daniella Lent-Schochet, Ryan Silva, Matthew McLaughlin, Beverley Huet, Ishwarlal Jialal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Metabolic syndrome (MetS), a cardio-metabolic cluster afflicting 35% of American adults, increases cardiovascular disease (CVD) and type-2 diabetes (T2DM) risk. Increased levels of trimethylamine N-oxide (TMAO), a metabolite derived from choline and L-carnitine, correlates with CVD and T2DM. However, the precise role of TMAO and its precursors in MetS remains unclear. We tested the hypothesis that choline, L-carnitine and TMAO in MetS patients without CVD or T2DM would be altered and correlate with inflammatory markers. This was an exploratory study of 30 patients with nascent MetS (without CVD or T2DM) and 20 matched controls. MetS was defined by the Adult Treatment Panel III criteria. TMAO and its precursors were evaluated from each patient's frozen early morning urine samples and quantified using liquid chromatography/mass spectrometry (LC-MS). These amines were correlated with a detailed repertoire of biomarkers of inflammation and adipokines. L-carnitine was significantly increased (p = 0.0002) compared to controls. There was a trend for a significant increase in TMAO levels (p = 0.08). Choline was not significantly altered in MetS. L-carnitine correlated significantly with soluble tumor necrosis factor 1 (sTNFR1) and leptin, and inversely to adiponectin. TMAO correlated with IL-6, endotoxin and chemerin. Neither choline, nor L-carnitine significantly correlated with TMAO. L-carnitine is directly correlated with markers of inflammation in nascent MetS. Cellular L-carnitine could be a biomediator or marker of inflammation in the pathogenesis of MetS, and the sequelae of CVD and T2DM.

Original languageEnglish (US)
Article number20180015
JournalUnknown Journal
DOIs
StateAccepted/In press - Apr 18 2018

Fingerprint

Carnitine
Choline
Cardiovascular Diseases
Inflammation
Adipokines
trimethyloxamine
Adiponectin
Leptin
Endotoxins
Liquid Chromatography
Type 2 Diabetes Mellitus
Amines
Interleukin-6
Mass Spectrometry
Tumor Necrosis Factor-alpha
Biomarkers
Urine

Keywords

  • choline
  • inflammation
  • L-carnitine
  • metabolic syndrome
  • trimethylamine N-oxide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Endocrinology

Cite this

Lent-Schochet, D., Silva, R., McLaughlin, M., Huet, B., & Jialal, I. (Accepted/In press). Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. Unknown Journal, [20180015]. https://doi.org/10.1515/hmbci-2018-0015

Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. / Lent-Schochet, Daniella; Silva, Ryan; McLaughlin, Matthew; Huet, Beverley; Jialal, Ishwarlal.

In: Unknown Journal, 18.04.2018.

Research output: Contribution to journalArticle

Lent-Schochet, Daniella ; Silva, Ryan ; McLaughlin, Matthew ; Huet, Beverley ; Jialal, Ishwarlal. / Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. In: Unknown Journal. 2018.
@article{b07b0d4886c74a728d1f554ceaaf3cd8,
title = "Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome",
abstract = "Metabolic syndrome (MetS), a cardio-metabolic cluster afflicting 35{\%} of American adults, increases cardiovascular disease (CVD) and type-2 diabetes (T2DM) risk. Increased levels of trimethylamine N-oxide (TMAO), a metabolite derived from choline and L-carnitine, correlates with CVD and T2DM. However, the precise role of TMAO and its precursors in MetS remains unclear. We tested the hypothesis that choline, L-carnitine and TMAO in MetS patients without CVD or T2DM would be altered and correlate with inflammatory markers. This was an exploratory study of 30 patients with nascent MetS (without CVD or T2DM) and 20 matched controls. MetS was defined by the Adult Treatment Panel III criteria. TMAO and its precursors were evaluated from each patient's frozen early morning urine samples and quantified using liquid chromatography/mass spectrometry (LC-MS). These amines were correlated with a detailed repertoire of biomarkers of inflammation and adipokines. L-carnitine was significantly increased (p = 0.0002) compared to controls. There was a trend for a significant increase in TMAO levels (p = 0.08). Choline was not significantly altered in MetS. L-carnitine correlated significantly with soluble tumor necrosis factor 1 (sTNFR1) and leptin, and inversely to adiponectin. TMAO correlated with IL-6, endotoxin and chemerin. Neither choline, nor L-carnitine significantly correlated with TMAO. L-carnitine is directly correlated with markers of inflammation in nascent MetS. Cellular L-carnitine could be a biomediator or marker of inflammation in the pathogenesis of MetS, and the sequelae of CVD and T2DM.",
keywords = "choline, inflammation, L-carnitine, metabolic syndrome, trimethylamine N-oxide",
author = "Daniella Lent-Schochet and Ryan Silva and Matthew McLaughlin and Beverley Huet and Ishwarlal Jialal",
year = "2018",
month = "4",
day = "18",
doi = "10.1515/hmbci-2018-0015",
language = "English (US)",
journal = "Seminars in Fetal and Neonatal Medicine",
issn = "1744-165X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome

AU - Lent-Schochet, Daniella

AU - Silva, Ryan

AU - McLaughlin, Matthew

AU - Huet, Beverley

AU - Jialal, Ishwarlal

PY - 2018/4/18

Y1 - 2018/4/18

N2 - Metabolic syndrome (MetS), a cardio-metabolic cluster afflicting 35% of American adults, increases cardiovascular disease (CVD) and type-2 diabetes (T2DM) risk. Increased levels of trimethylamine N-oxide (TMAO), a metabolite derived from choline and L-carnitine, correlates with CVD and T2DM. However, the precise role of TMAO and its precursors in MetS remains unclear. We tested the hypothesis that choline, L-carnitine and TMAO in MetS patients without CVD or T2DM would be altered and correlate with inflammatory markers. This was an exploratory study of 30 patients with nascent MetS (without CVD or T2DM) and 20 matched controls. MetS was defined by the Adult Treatment Panel III criteria. TMAO and its precursors were evaluated from each patient's frozen early morning urine samples and quantified using liquid chromatography/mass spectrometry (LC-MS). These amines were correlated with a detailed repertoire of biomarkers of inflammation and adipokines. L-carnitine was significantly increased (p = 0.0002) compared to controls. There was a trend for a significant increase in TMAO levels (p = 0.08). Choline was not significantly altered in MetS. L-carnitine correlated significantly with soluble tumor necrosis factor 1 (sTNFR1) and leptin, and inversely to adiponectin. TMAO correlated with IL-6, endotoxin and chemerin. Neither choline, nor L-carnitine significantly correlated with TMAO. L-carnitine is directly correlated with markers of inflammation in nascent MetS. Cellular L-carnitine could be a biomediator or marker of inflammation in the pathogenesis of MetS, and the sequelae of CVD and T2DM.

AB - Metabolic syndrome (MetS), a cardio-metabolic cluster afflicting 35% of American adults, increases cardiovascular disease (CVD) and type-2 diabetes (T2DM) risk. Increased levels of trimethylamine N-oxide (TMAO), a metabolite derived from choline and L-carnitine, correlates with CVD and T2DM. However, the precise role of TMAO and its precursors in MetS remains unclear. We tested the hypothesis that choline, L-carnitine and TMAO in MetS patients without CVD or T2DM would be altered and correlate with inflammatory markers. This was an exploratory study of 30 patients with nascent MetS (without CVD or T2DM) and 20 matched controls. MetS was defined by the Adult Treatment Panel III criteria. TMAO and its precursors were evaluated from each patient's frozen early morning urine samples and quantified using liquid chromatography/mass spectrometry (LC-MS). These amines were correlated with a detailed repertoire of biomarkers of inflammation and adipokines. L-carnitine was significantly increased (p = 0.0002) compared to controls. There was a trend for a significant increase in TMAO levels (p = 0.08). Choline was not significantly altered in MetS. L-carnitine correlated significantly with soluble tumor necrosis factor 1 (sTNFR1) and leptin, and inversely to adiponectin. TMAO correlated with IL-6, endotoxin and chemerin. Neither choline, nor L-carnitine significantly correlated with TMAO. L-carnitine is directly correlated with markers of inflammation in nascent MetS. Cellular L-carnitine could be a biomediator or marker of inflammation in the pathogenesis of MetS, and the sequelae of CVD and T2DM.

KW - choline

KW - inflammation

KW - L-carnitine

KW - metabolic syndrome

KW - trimethylamine N-oxide

UR - http://www.scopus.com/inward/record.url?scp=85046037999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046037999&partnerID=8YFLogxK

U2 - 10.1515/hmbci-2018-0015

DO - 10.1515/hmbci-2018-0015

M3 - Article

C2 - 29668463

AN - SCOPUS:85046037999

JO - Seminars in Fetal and Neonatal Medicine

JF - Seminars in Fetal and Neonatal Medicine

SN - 1744-165X

M1 - 20180015

ER -